This project evaluates the effectiveness of the administration of autologous bone marrow blood in patients with brittle type 1 diabetes mellitus to restore insulin secretion. After mobilization of hematopoietic progenitors (G-CSF) during 3 days, 50 to 90 mL of bone marrow blood will be obtained by multifunction in the posterior iliac crest. The material obtained will be implanted into the pancreas through the magna pancreatic artery after femoral catheterization.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
3
administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
Enric Esmatjes
Barcelona, Barcelona, Spain
Hospital Clinic
Barcelona, Barcelona, Spain
Evaluate glycosylated hemoglobin 1,3,6, and 12 months after autologous bone marrow blood administration.
Time frame: 12 months
Evaluate number of hypoglycemias 1,3,6, and 12 months after autologous bone marrow blood administration.
Time frame: 12 months
Evaluate insulin dose 1,3,6, and 12 months after autologous bone marrow blood administration.
Time frame: 12 months
Evaluate GADab titers and treatment tolerance 1,3,6, and 12 months after autologous bone marrow blood administration.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.